Literature DB >> 9482915

Mice with type 2 and 3 Gaucher disease point mutations generated by a single insertion mutagenesis procedure.

Y Liu1, K Suzuki, J D Reed, A Grinberg, H Westphal, A Hoffmann, T Döring, K Sandhoff, R L Proia.   

Abstract

Gaucher disease is caused by mutations in the gene encoding the lysosomal enzyme glucocerebrosidase (GC). Three clinical types of Gaucher disease have been defined according to the presence (type 2 and 3) or absence (type 1) of central nervous system disease and severity of clinical manifestations. The clinical course of the disease correlates with the mutation carried by the GC gene. To produce mice with point mutations that correspond to the clinical types of Gaucher disease, we have devised a highly efficient one-step mutagenesis method-the single insertion mutagenesis procedure (SIMP)-to introduce human disease mutations into the mouse GC gene. By using SIMP, mice were generated carrying either the very severe RecNciI mutation that can cause type 2 disease or the less severe L444P mutation associated with type 3 disease. Mice homozygous for the RecNciI mutation had little GC enzyme activity and accumulated glucosylceramide in brain and liver. In contrast, the mice homozygous for the L444P mutation had higher levels of GC activity and no detectable accumulation of glucosylceramide in brain and liver. Surprisingly, both point mutation mice died within 48 hr of birth, apparently of a compromised epidermal permeability barrier caused by defective glucosylceramide metabolism in the epidermis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9482915      PMCID: PMC19391          DOI: 10.1073/pnas.95.5.2503

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairment.

Authors:  Y Liu; A Hoffmann; A Grinberg; H Westphal; M P McDonald; K M Miller; J N Crawley; K Sandhoff; K Suzuki; R L Proia
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

Review 2.  Gaucher disease.

Authors:  D Balicki; E Beutler
Journal:  Medicine (Baltimore)       Date:  1995-11       Impact factor: 1.889

3.  The clinical, molecular, and pathological characterisation of a family with two cases of lethal perinatal type 2 Gaucher disease.

Authors:  E Sidransky; N Tayebi; B K Stubblefield; W Eliason; A Klineburgess; G P Pizzolato; J N Cox; J Porta; A Bottani; C D DeLozier-Blanchet
Journal:  J Med Genet       Date:  1996-02       Impact factor: 6.318

4.  Expression of mutated glucocerebrosidase alleles in human cells.

Authors:  M Pasmanik-Chor; L Madar-Shapiro; E O Stein; H Aerts; S Gatt; M Horowitz
Journal:  Hum Mol Genet       Date:  1997-06       Impact factor: 6.150

5.  Glucosylceramide metabolism is regulated during normal and hormonally stimulated epidermal barrier development in the rat.

Authors:  K Hanley; Y Jiang; W M Holleran; P M Elias; M L Williams; K R Feingold
Journal:  J Lipid Res       Date:  1997-03       Impact factor: 5.922

6.  Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes.

Authors:  S L Mansour; K R Thomas; M R Capecchi
Journal:  Nature       Date:  1988-11-24       Impact factor: 49.962

Review 7.  The double-strand-break repair model for recombination.

Authors:  J W Szostak; T L Orr-Weaver; R J Rothstein; F W Stahl
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

8.  Metaxin, a gene contiguous to both thrombospondin 3 and glucocerebrosidase, is required for embryonic development in the mouse: implications for Gaucher disease.

Authors:  P Bornstein; C E McKinney; M E LaMarca; S Winfield; T Shingu; S Devarayalu; H L Vos; E I Ginns
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

9.  Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism.

Authors:  K Sango; S Yamanaka; A Hoffmann; Y Okuda; A Grinberg; H Westphal; M P McDonald; J N Crawley; K Sandhoff; K Suzuki; R L Proia
Journal:  Nat Genet       Date:  1995-10       Impact factor: 38.330

10.  Congenital ichthyosis preceding neurologic symptoms in two sibs with type 2 Gaucher disease.

Authors:  A Fujimoto; N Tayebi; E Sidransky
Journal:  Am J Med Genet       Date:  1995-11-20
View more
  35 in total

1.  Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease.

Authors:  Ying Sun; Benjamin Liou; You-Hai Xu; Brian Quinn; Wujuan Zhang; Rick Hamler; Kenneth D R Setchell; Gregory A Grabowski
Journal:  J Biol Chem       Date:  2011-12-13       Impact factor: 5.157

Review 2.  Lysosomal enzyme replacement therapies: Historical development, clinical outcomes, and future perspectives.

Authors:  Melani Solomon; Silvia Muro
Journal:  Adv Drug Deliv Rev       Date:  2017-05-11       Impact factor: 15.470

Review 3.  Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.

Authors:  Kenneth J Valenzano; Richie Khanna; Allan C Powe; Robert Boyd; Gary Lee; John J Flanagan; Elfrida R Benjamin
Journal:  Assay Drug Dev Technol       Date:  2011-06       Impact factor: 1.738

4.  The increased sensitivity of neurons with elevated glucocerebroside to neurotoxic agents can be reversed by imiglucerase.

Authors:  D Pelled; H Shogomori; A H Futerman
Journal:  J Inherit Metab Dis       Date:  2000-03       Impact factor: 4.982

Review 5.  Gene therapy for lysosomal storage diseases (LSDs) in large animal models.

Authors:  Mark Haskins
Journal:  ILAR J       Date:  2009

Review 6.  Animal models for metabolic, neuromuscular and ophthalmological rare diseases.

Authors:  Guillaume Vaquer; Frida Rivière; Maria Mavris; Fabrizia Bignami; Jordi Llinares-Garcia; Kerstin Westermark; Bruno Sepodes
Journal:  Nat Rev Drug Discov       Date:  2013-03-15       Impact factor: 84.694

7.  Murine models of acute neuronopathic Gaucher disease.

Authors:  Ida Berglin Enquist; Christophe Lo Bianco; Andreas Ooka; Eva Nilsson; Jan-Eric Månsson; Mats Ehinger; Johan Richter; Roscoe O Brady; Deniz Kirik; Stefan Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-22       Impact factor: 11.205

8.  Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels.

Authors:  You-Hai Xu; Rachel Reboulet; Brian Quinn; Joerg Huelsken; David Witte; Gregory A Grabowski
Journal:  Mol Genet Metab       Date:  2008-03-17       Impact factor: 4.797

9.  Upregulation of proinflammatory cytokines in the fetal brain of the Gaucher mouse.

Authors:  Young Bin Hong; Eun Young Kim; Sung-Chul Jung
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

10.  In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse models.

Authors:  Ying Sun; Benjamin Liou; Brian Quinn; Huimin Ran; You-Hai Xu; Gregory A Grabowski
Journal:  PLoS One       Date:  2009-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.